Sign up USA
Proactive Investors - Run By Investors For Investors

Kura Oncology shares double after successful results from phase II trial of lead candidate

Kura revealed late on Thursday that its tipifarnib head and neck cancer (NNSCC) candidate had achieved its primary endpoint before enrolment had even finished
cancer cells under a microscope
Head and neck cancer is one of the leading causes of cancer-related deaths worldwide

The market value of Kura Oncology Inc (NASDAQ:KURA) almost doubled on Friday morning after the biopharma announced positive results from phase II study of its lead cancer treatment.

Kura revealed late on Thursday that its tipifarnib head and neck cancer (NNSCC) candidate had achieved its primary endpoint before enrolment had even finished.

To be considered a success, the trial needed four confirmed partial responses to meet achieve the endpoint.

From the first six patients alone, four had confirmed partial responses while two others had disease stabilisation.

“We have observed rapid and, in some cases, dramatic responses in patients with relapsed and/or refractory HNSCC who do not appear to benefit from other therapies," said chief medical officer Antonio Gualberto.

“Based on these very encouraging results, we are exploring available options to advance the development of tipifarnib in this patient population as quickly as possible.”

Kura shares surged 89% in early deals to US$12.95.

View full KURA profile View Profile

Kura Oncology Timeline

Related Articles

boy leaning against chain link fence
September 14 2017
We take a look back at the progress made by Summit in the five years since we first spoke to chief executive Glyn Edwards
Cancer cells
September 05 2017
In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample
picture of drug research
August 22 2017
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use